Sun Pharma Reports Five Year Results of Ilumya (tildrakizumab-asmn) in P-III Studies for Moderate-to-Severe Plaque Psoriasis
Shots:
- The P-III extension studies (reSURFACE 1 & reSURFACE 2) involves assessing Ilumya (100 & 200mg) vs PBO in moderate-to-severe PsO participants with at least 50% improvement in PASI 50 at base study completion who received Ilumya within 12wks. of base study end (52 or 64wks.) were eligible to enroll in the extension study & continued on the same Ilumya dose vs PBO (q12w)
- Results: Ilumya (100 mg) @244wks.- PASI 90 & PASI 100 (65.9% & 32.8%); PASI75 (88.7%). In long-term analyses- absolute PASI <1/<3/<5 scores @28wks. (50.8%- 85.1% & 96.4%- respectively) were sustained @244wks. (47.7%- 78.8% & 88.7%) respectively. Additional data results presented provide insight into the positive long-term safety profile for Ilumya in five year
- Ilumya is a humanized lgG1/k mAb- targeting the p19 subunit of IL-23 & inhibit its interaction with the IL-23 receptor and is approved in Australia- Japan & EU for PsO
Ref: PRNewswire | Image: Business Standard
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com